DRTS News and Press, Alpha Tau Medical Ltd. From 03/07/24

2024-03-07 17:37:55 ET More on Alpha Tau Medical Seeking Alpha’s Quant Rating on Alpha Tau Medical Historical earnings data for Alpha Tau Medical Financial information for Alpha Tau Medical Read the full article on Seeking Alpha For further det...

- Positive interim safety and feasibility data from pancreatic cancer study in Montreal , with initial signs of potential dose response findings - - ReSTART U.S. multi-center pivotal trial currently underway - - Submitted PMDA appl...

JERUSALEM, Feb. 26, 2024 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, today announced that management will participate at the Barclays 26 th An...

- The overview presentation will review some of the Company’s recent achievements, including highly promising interim results from the Company’s pancreatic cancer safety and feasibility trial as well as robust long-term data analyzed across four clinical trials - - The Com...

JERUSALEM, Nov. 29, 2023 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, today announced that management will present at the Sidoti Small-Cap Virtual ...

- Interim data read-out of the first five treated patients demonstrated successful delivery in all five cases, as well as no product-related Serious Adverse Events - - First five patients received conservative partial tumor coverage, and in patients with higher radium-224 levels, increa...

JERUSALEM, Nov. 20, 2023 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau") (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, and HekaBio K.K. (“HekaBio”) a Japan-based healthcare investment, development and commercializa...

Alpha Tau Medical Ltd. (DRTS) is expected to report $-0.12 for Q3 2023

2023-11-16 16:46:50 ET More on Alpha Tau Medical Alpha Tau Medical files to sell 1.1M ordinary shares for holders Alpha Tau Medical GAAP EPS of -$0.24, revenue of $12.26M Seeking Alpha’s Quant Rating on Alpha Tau Medical Historical earnings data for Al...

- Treated the first patient with advanced inoperable pancreatic cancer at Hadassah Medical Center in Israel in September, alongside safety and feasibility trial in similar indication currently underway in Montreal, Canada - - 89% CR, two-year local recurrence-free survival of 77%, and n...